Literature DB >> 20826585

Statins inhibit growth of human theca-interstitial cells in PCOS and non-PCOS tissues independently of cholesterol availability.

Anna Sokalska1, Piotr C Piotrowski, Izabela J Rzepczynska, Amanda Cress, Antoni J Duleba.   

Abstract

CONTEXT: Polycystic ovary syndrome (PCOS) is associated with ovarian enlargement, prominent theca-interstitial hyperplasia, and excessive androgen production. Recent clinical trials have demonstrated that statins, 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors, decrease androgen levels in women with PCOS.
OBJECTIVE: The present study evaluated the effect of statins on proliferation of human ovarian theca-interstitial cells. DESIGN AND SETTINGS: In vitro experiments were performed in the university research laboratory. PATIENTS: Human theca-interstitial cells were isolated from ovaries of PCOS (n=4) and non-PCOS (n=4) patients. MAIN OUTCOME MEASURES: The cells were incubated for 48 h without additives (control) or with simvastatin (3-30 μm), mevastatin (3-30 μm), and/or the cell- and mitochondrion-permeable form of cholesterol (22-hydroxycholesterol; 10 μm). To determine whether the effects of statins could be affected by leukocytes, the experiment was carried out on cells not purified of leukocytes and cells purified using anti-CD-45 immunomagnetic beads. The effect of statins on proliferation was evaluated by determination of DNA synthesis using radiolabeled thymidine-incorporation assay and by quantification of viable cells using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenil)-2H-tetrazolium assay.
RESULTS: Statins induced an inhibition of DNA synthesis in both the absence and the presence of 22-hydroxycholesterol; furthermore, 22-hydroxycholesterol alone also inhibited DNA synthesis. These effects of statins and 22-hydroxycholesterol were confirmed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenil)-2H-tetrazolium assay. Comparable inhibition of proliferation was observed in cells obtained from women with and without PCOS and in cell preparations treated and not treated with anti-CD-45 immunomagnetic beads.
CONCLUSIONS: Statins inhibit proliferation of human theca-interstitial cells irrespective of the availability of cholesterol and independently of leukocytes both in normal and PCOS ovaries.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826585      PMCID: PMC2999973          DOI: 10.1210/jc.2010-0770

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Proliferation of ovarian theca-interstitial cells is modulated by antioxidants and oxidative stress.

Authors:  A J Duleba; N Foyouzi; M Karaca; T Pehlivan; J Kwintkiewicz; H R Behrman
Journal:  Hum Reprod       Date:  2004-06-03       Impact factor: 6.918

Review 2.  Antioxidative effects of statins.

Authors:  Oliver Adam; Ulrich Laufs
Journal:  Arch Toxicol       Date:  2008-08-01       Impact factor: 5.153

3.  Suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and inhibition of growth of human fibroblasts by 7-ketocholesterol.

Authors:  M S Brown; J L Goldstein
Journal:  J Biol Chem       Date:  1974-11-25       Impact factor: 5.157

4.  Mevastatin inhibits proliferation of rat ovarian theca-interstitial cells by blocking the mitogen-activated protein kinase pathway.

Authors:  Jakub Kwintkiewicz; Nastaran Foyouzi; Piotr Piotrowski; Izabela Rzepczynska; Antoni J Duleba
Journal:  Fertil Steril       Date:  2006-09-11       Impact factor: 7.329

5.  Effects of insulin and insulin-like growth factors on proliferation of rat ovarian theca-interstitial cells.

Authors:  A J Duleba; R Z Spaczynski; D L Olive; H R Behrman
Journal:  Biol Reprod       Date:  1997-04       Impact factor: 4.285

6.  Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial.

Authors:  Beata Banaszewska; Leszek Pawelczyk; Robert Z Spaczynski; James Dziura; Antoni J Duleba
Journal:  J Clin Endocrinol Metab       Date:  2006-11-14       Impact factor: 5.958

7.  Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial.

Authors:  Antoni J Duleba; Beata Banaszewska; Robert Z Spaczynski; Leszek Pawelczyk
Journal:  Fertil Steril       Date:  2006-03-09       Impact factor: 7.329

8.  Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis.

Authors:  Daniel Izquierdo; Nastaran Foyouzi; Jakub Kwintkiewicz; Antoni J Duleba
Journal:  Fertil Steril       Date:  2004-10       Impact factor: 7.329

9.  The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.

Authors:  Thozhukat Sathyapalan; Eric S Kilpatrick; Anne-Marie Coady; Stephen L Atkin
Journal:  J Clin Endocrinol Metab       Date:  2008-10-21       Impact factor: 5.958

Review 10.  Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called "hyperthecosis".

Authors:  P E Hughesdon
Journal:  Obstet Gynecol Surv       Date:  1982-02       Impact factor: 2.347

View more
  15 in total

Review 1.  Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome.

Authors:  Selma F Witchel; Sergio E Recabarren; Frank González; Evanthia Diamanti-Kandarakis; Kai I Cheang; Antoni J Duleba; Richard S Legro; Roy Homburg; Renato Pasquali; Rogerio A Lobo; Christos C Zouboulis; Fahrettin Kelestimur; Franca Fruzzetti; Walter Futterweit; Robert J Norman; David H Abbott
Journal:  Endocrine       Date:  2012-06-04       Impact factor: 3.633

2.  Comparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells.

Authors:  Anna Sokalska; Scott D Stanley; Jesus A Villanueva; Israel Ortega; Antoni J Duleba
Journal:  Biol Reprod       Date:  2014-02-27       Impact factor: 4.285

3.  Glucose-stimulated oxidative stress in mononuclear cells is related to pancreatic β-cell dysfunction in polycystic ovary syndrome.

Authors:  Steven K Malin; John P Kirwan; Chang Ling Sia; Frank González
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

4.  Evidence of mononuclear cell preactivation in the fasting state in polycystic ovary syndrome.

Authors:  Frank González; John P Kirwan; Neal S Rote; Judi Minium
Journal:  Am J Obstet Gynecol       Date:  2014-06-20       Impact factor: 8.661

5.  Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment.

Authors:  Beata Banaszewska; Leszek Pawelczyk; Robert Z Spaczynski; Antoni J Duleba
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

6.  Simvastatin reduces steroidogenesis by inhibiting Cyp17a1 gene expression in rat ovarian theca-interstitial cells.

Authors:  Israel Ortega; Amanda B Cress; Donna H Wong; Jesus A Villanueva; Anna Sokalska; Ben C Moeller; Scott D Stanley; Antoni J Duleba
Journal:  Biol Reprod       Date:  2012-01-30       Impact factor: 4.285

7.  Inflammation in response to glucose ingestion is independent of excess abdominal adiposity in normal-weight women with polycystic ovary syndrome.

Authors:  Frank González; Chang Ling Sia; Marguerite K Shepard; Neal S Rote; Judi Minium
Journal:  J Clin Endocrinol Metab       Date:  2012-08-17       Impact factor: 5.958

8.  Hyperglycemia-induced oxidative stress is independent of excess abdominal adiposity in normal-weight women with polycystic ovary syndrome.

Authors:  Frank González; Chang Ling Sia; Marguerite K Shepard; Neal S Rote; Judi Minium
Journal:  Hum Reprod       Date:  2012-08-30       Impact factor: 6.918

9.  The altered mononuclear cell-derived cytokine response to glucose ingestion is not regulated by excess adiposity in polycystic ovary syndrome.

Authors:  Frank González; Chang Ling Sia; Marguerite K Shepard; Neal S Rote; Judi Minium
Journal:  J Clin Endocrinol Metab       Date:  2014-07-31       Impact factor: 5.958

Review 10.  The management of patients with polycystic ovary syndrome.

Authors:  Channa N Jayasena; Stephen Franks
Journal:  Nat Rev Endocrinol       Date:  2014-07-15       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.